As bluebird bio struggles to get its gene therapies over the finishing line, the company says its financial position raises "substantial doubt" about its ability to continue as a going concern.

The biggest stories of the day delivered to your inbox.

Have you seen something interesting? Click Submit to share your rare bird sightings via our simple form.